Exclusive advisory to the shareholder of Plantafood Medical on the majority sale to IBEX Wachstumspartner
Manfred Scheffler
With IBEX as new growth partner, Plantafood Medical secures long-term succession and aims to expand its leadership in high-quality nutritional supplements.
February, 2025. ox8 Corporate Finance has acted as exclusive M&A advisor to the shareholders of Plantafood Medical GmbH (“Plantafood”) on the sale of a majority stake in the company to IBEX Wachstumspartner GmbH (“IBEX”).
IBEX has acquired a stake in the dietary supplement specialist Plantafood Medical. As a manufacturing partner, the company researches, develops and produces a comprehensive range of supplements on behalf of its customers and is one of the German market leaders for health-orientated combination products.
Founded in 2001 by Mr Manfred Scheffler, Plantafood Medical can look back on an extremely successful development. The company has been growing at an above-average rate for many years and is constantly gaining market share thanks to its quality leadership. Today, more than 120 employees in Germany develop and produce specialised food supplements for a large number of national and international supplement brands from various industries in a wide range of application areas. The company offers its customers a full range of services in research, development, production and sales support for capsules, tablets, powders and other dosage forms and is characterised above all by the highest quality standards, its nutritional focus and flexibility.
| Mandate: | Sell-Side |
| Client: | Plantafood Medical GmbH (Germany) |
| Investor: | IBEX Wachstumspartner GmbH (Germany) |
| Transaction: | Majority Sale |
| Volume: | Not Public |
Manfred Scheffler, founder of Plantafood: “I am very pleased to have placed Plantafood Medical in good hands. IBEX gave me a good feeling right from the first meeting, was a trustworthy transaction partner throughout the entire process and in Dr Grosselfinger I have also found my ideal successor. All in all, a really great result and exactly what I wanted for my succession and the future of Plantafood Medical. I am particularly pleased that my children, Annalena and Sven Scheffler, will remain part of the company and will actively shape the future of Plantafood Medical together with IBEX. I wish Dr Grosselfinger, my children, the employees and IBEX every success for the future and for the further development of the company.“
Reflecting on the collaboration with ox8 Corporate Finance, Manfred Scheffler shares: “The ox8 team has excellent market know-ledge and contacts at both national and international level. The coordination of the entire process was extremely competent and pleasant, and the ox8 colleagues were always available – even at night or at weekends. Furthermore, the cooperation was also excellent on an interpersonal level. It couldn’t have been much better!”
Jan Dreesen, Managing Director of IBEX, adds: “We are delighted to be a new partner of Plantafood Medical and look forward to further investing in the growth and development of the company. The market for dietary supplements is growing steadily and Plantafood Medical is ideally positioned to further expand its position as a quality leader and to further strengthen its core competences in research and development. With Dr Christian Grosselfinger as Managing Director and the rest of the management team, we also have a strong management team that will continue Mr Scheffler’s entrepreneurial success.”
Mr Scheffler will remain with the company for a transitional period to ensure a smooth continuation of the high service quality for customers and an orderly handover in the course of the succession.
IBEX was advised on the transaction by Taylor Wessing (legal and structuring), AC Christes (tax and financial) and Gracher (financing). Manfred Scheffler was advised by Görgen & Partner (personal advisor), Görg (legal) and ox8 Corporate Finance (transaction advisory).
